

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

| | | |
|---|-------------------------------|---|
| POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM | Application Number | 10/552,493 |
| | Filing Date | 7 April 2004 |
| | First Named Inventor | Daniele ANDREOTTI |
| | Title | CONDENSED N-HETEROCYCL COMPOUNDS ... |
| | Art Unit | |
| | Examiner Name | |
| | Attorney Docket Number | PB60162 |

I hereby appoint:

☒ **Practitioners associated with the Customer Numbers.** 20462

Or

☐ Practitioner(s) named below:

Name

Registration Number

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☐ The address associated with the above-mentioned Customer Number:

Or

☒ **The address associated with Customer Number 20462**

Or

☐ **Firm or Individual Name:**

Address:

Address:

City:

State:

Zip:

Country:

Telephone:

Fax:

I am the:

☐ Applicant/Inventor:☒ Assignee or record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature:

Date:

Name: Stephen Venetianer

Telephone: 610-270-5040

Title and Company: Attorney and Authorised Official SB Pharmco Puerto Rico Inc

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of: _____ forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: SB Pharmco Puerto Rico Inc****Application No./Patent No.: 10/552,493 Filed/Issue Date: 7 April 2004****Entitled: CONDENSED N-HETEROCYCLIC COMPOUNDS AND THIER
USE AS CRF RECEPTOR ANTAGONISTS****SB Pharmco Puerto Rico Inc, a corporation, states that it is:**1. ☐ the assignee of the entire right, title, and interest; or2. ☒ an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is 50 % in the patent application/patent identified above by virtue of either;


A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

December 6, 2005

Date

Stephen Venetianer

Printed or Typed Name

610-270-5040

Telephone Number

Attorney and Authorised Official SB Pharmco Puerto Rico Inc

Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

| | | |
|---|-------------------------------|--|
| POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM | Application Number | 10/552,493 |
| | Filing Date | 7 April 2004 |
| | First Named Inventor | Daniele ANDREOTTI |
| | Title | CONDENSED N-HETEROCYCLIC COMPOUNDS ... |
| | Art Unit | |
| | Examiner Name | |
| | Attorney Docket Number | PB60162 |

I hereby appoint:

☒ **Practitioners associated with the Customer Numbers. 20462**

Or

☐ Practitioner(s) named below:

| Name | Registration Number |
|------|---------------------|
| | |

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☐ The address associated with the above-mentioned Customer Number:

Or

☒ **The address associated with Customer Number 20462**

Or

☐ Firm or Individual Name:


| | |
|------------|-------------|
| Address: | |
| Address: | |
| City: | State: Zip: |
| Country: | |
| Telephone: | Fax: |

I am the:

☐ Applicant/Inventor:

☒ Assignee or record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

| | |
|--|-------------------------|
| Signature:  | Date: 12/2/05 |
| Name: Margaret Valeur-Jensen | Telephone: 858-617-7670 |

Title and Company: General Counsel and Corporate Secretary, Neurocrine Biosciences, Inc.

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of: forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Neurocrine Biosciences Inc****Application No./Patent No.: 10/552,493 Filed/Issue Date: 7 April 2004****Entitled: CONDENSED N-HETEROCYCLIC COMPOUNDS AND THIER
USE AS CRF RECEPTOR ANTAGONISTS****Neurocrine Biosciences Inc, a corporation, states that it is:**1. ☐ the assignee of the entire right, title, and interest; or2. ☒ an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is 50 % in the patent application/patent identified above by virtue of either;


A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

12/2/05

Date

Margaret Valeur-Jensen

Printed or Typed Name

858-617-7670

Telephone Number

General Counsel and Corporate Secretary

Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

WHEREAS I/WE, Daniele ANDREOTTI, Giovanni BERNASCONI, Emiliano CASTIGLIONI, Stefania Anne CONTINI, Romano DI FABIO, Elettra FAZZOLARI, Aldo FERIANI, Gabriella GENTILE, Mario MATTIOLI, Anna MINGARDI, FabioMaria SABBATINI, Yves ST-DENIS, of Verona, Italy (hereinafter called "the inventor(s)") have invented or discovered " **CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS**" (hereinafter called "the invention") for which a patent application No. **0308208.8** was filed on **9 April 2003** in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

(PCT Application No. **PCT/IB2004/001350** filed **7 April 2004**)

WHEREAS the invention, being made in the course of my employment, belongs to my/our employer, namely **GLAXOSMITHKLINE SpA**, a company incorporated in Italy whose registered address is Via Alessandro Fleming 2, 37100 Verona, Italy, and

GLAXOSMITHKLINE SpA have authorised and requested my/our making the application, and

WHEREAS SB Pharmco Puerto Rico Inc., a company incorporated in US whose registered address is: The Prentice Hall Corp System, c/o FGR Corporate Services, Inc, BBV Tower, 8th Floor, 254 Munoz Rivera Avenue, San Juan, Puerto Rico 00918, (formerly CSC, The United States Corporation Company, 105 Ponce de Leon Avenue, One Comptroller Plaza, Hato Rey, Puerto Rico 00917), a company incorporated in US whose registered address is and **Neurocrine Biosciences Inc** a company incorporated in US whose registered address is 12790 El Camino Real, San Diego, CA 92130, USA, (formerly of 10555 Science Center Drive, San Diego, California 92121, USA) is desirous of acquiring from **GLAXOSMITHKLINE SpA** the whole right, title and interest in and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by **GLAXOSMITHKLINE SpA** of the invention and the application and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to **GLAXOSMITHKLINE SpA** and **GLAXOSMITHKLINE SpA** in turn hereby assigns and transfers to **SB PHARMCO PUERTO RICO INC. and NEUROCRINE BIOSCIENCES INC** its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and **GLAXOSMITHKLINE SpA** hereby authorise and request any patent arising therefrom in the United States of America be issued to **SB PHARMCO PUERTO RICO INC. and NEUROCRINE BIOSCIENCES INC**

AND **GLAXOSMITHKLINE SpA** hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **SB PHARMCO PUERTO RICO INC. and NEUROCRINE BIOSCIENCES INC**, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IN WITNESS whereof and with effect from 9 April 2003 the inventor(s) and **Peter John GIDDINGS** as Attorney of **GLAXOSMITHKLINE SpA** by virtue of a Power

of Attorney granted by **GLAXOSMITHKLINE SpA** have hereunto set their respective hands.


SIGNED by **Daniele ANDREOTTI**

Date: 17/10/2005


SIGNED by **Giovanni BERNASCONI**

Date: 13/10/2005


SIGNED by **Emiliano CASTIGLIONI**

Date: 10/11/05


SIGNED by **Stefania Anne CONTINI**

Date: 25-10-05


SIGNED by **Romano DI FABIO**

Date: 10.11.05


SIGNED by **Elettra FAZZOLARI**

Date: 19/10/05


SIGNED by **Aldo FERIANI**

Date: 20/10/05


SIGNED by **Gabriella GENTILE**


Date: 11/11/05


SIGNED by **Mario MATTIOLI**

Date: 18/10/2005


SIGNED by **Anna MINGARDI**


Date: 17/10/2005


SIGNED by **Fabio Maria SABBATINI**

Date: 13/10/2005


SIGNED by **Yves ST-DENIS**

Date: 13/10/2005


SIGNED by **Peter John GIDDINGS**
as the Attorney of
GLAXOSMITHKLINE SPA

Date: 17 NOV 2005